Sigyn Therapeutics (SIGY) EBITDA Margin (2017 - 2020)
Sigyn Therapeutics (SIGY) posted EBITDA Margin of 5294.13% for Q3 2020, up 79.26% sequentially from 25526.32% in Q1 2020, and down 491181.0% YoY from N/an in Q4 2019.
Sigyn Therapeutics (SIGY) EBITDA Margin (2017 - 2020) Analysis & Trends
Sigyn Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 5294.13% in Q3 2020.
- Quarterly EBITDA Margin fell 491181.0% year-over-year to 5294.13% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 5775.17% (down 531542.0% YoY) and the FY2019 annual result came in at 361.39%, up 318278.0% from the prior year.
- EBITDA Margin grew to 5294.13% in Q3 2020 per SIGY's latest filing, from 25526.32% in the prior quarter.
- Over five years, EBITDA Margin peaked at 24147900.0% in Q4 2018 and troughed at 25526.32% in Q1 2020.
- A 4-year average of 1722150.23% and a median of 249.72% in 2017 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2018 and 2019: EBITDA Margin surged 2000000000 bps in 2018, then slumped 2000000000 bps in 2019.
- Over 4 years, EBITDA Margin stood at 53.32% in 2017, then jumped by 45285955 bps to 24147900.0% in 2018, then slumped by 100 bps to 29.03% in 2019, then sank by 18136 bps to 5294.13% in 2020.
- According to Business Quant data, EBITDA Margin over the past three periods registered 5294.13%, 25526.32%, and 29.03% for Q3 2020, Q1 2020, and Q4 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 19.75% |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -5,294.13% |
| Mar 31, 2020 | -25,526.32% |
| Dec 31, 2019 | -29.03% |
| Sep 30, 2019 | -382.32% |
| Jun 30, 2019 | -157.50% |
| Mar 31, 2019 | -406.35% |
| Dec 31, 2018 | 24,147,900.00% |
| Sep 30, 2018 | -272.78% |
| Jun 30, 2018 | -4,039.60% |
| Mar 31, 2018 | -1,245.13% |
| Dec 31, 2017 | 53.32% |
| Sep 30, 2017 | -226.67% |
| Jun 30, 2017 | -142.26% |
| Mar 31, 2017 | -127.98% |